寻常疣市场
寻常疣市场：2026年市场规模约为27.3亿美元，2031年市场规模约为34.7亿美元；预测期复合年增长率为4.87%；当前最大市场为北美；增长最快的市场为亚太地区。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
寻常疣市场：2026年市场规模约为27.3亿美元，2031年市场规模约为34.7亿美元；预测期复合年增长率为4.87%；当前最大市场为北美；增长最快的市场为亚太地区。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 4.87% | 机构预测 |
| 市场规模 | 2026 | USD 2.73 billion | 机构预测 |
| 市场规模 | 2031 | USD 3.47 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| end_user | home care and self-treatment | 2025 | 47.290% |
| geography | North America | 2025 | 44.170% |
| lesion_profile | initial lesions | 2025 | 46.220% |
| patient_group | children and adolescents | 2025 | 46.310% |
| treatment_type | topical medications | 2025 | 43.870% |
关键结论
- end_user 维度中，home care and self-treatment 在 2025 年的公开份额为 47.29%。
- geography 维度中，North America 在 2025 年的公开份额为 44.17%。
- lesion_profile 维度中，initial lesions 在 2025 年的公开份额为 46.22%。
- patient_group 维度中，children and adolescents 在 2025 年的公开份额为 46.31%。
- treatment_type 维度中，topical medications 在 2025 年的公开份额为 43.87%。
主要参与者
- Bausch Health Companies Inc.
- Haleon plc
- Perrigo Company plc
- Prestige Consumer Healthcare Inc.
- Scholl’s Wellness Company
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Rising Treatment-Seeking from Persistent Lesions | +1.200% | Global, led by North America and Europe | Medium term (2-4 years) |
| OTC Access and Self-Care Adoption | +1.000% | Global, strongest in North America and Asia-Pacific | Short term (≤ 2 years) |
| Expansion of Dermatology and Teledermatology Access | +0.800% | North America and APAC core, spill-over to MEA | Medium term (2-4 years) |
| Demand for Minimally Invasive, Patient-Friendly Therapies | +0.700% | Global, concentrated in Europe and North America | Medium term (2-4 years) |
| Pipeline Validation of Disease-Modifying Immunotherapies | +0.600% | North America and Japan, expanding to Asia | Long term (≥ 4 years) |
| HPV-Targeted Topicals for Recalcitrant Disease | +0.500% | North America, Europe, Japan | Long term (≥ 4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Spontaneous Resolution and Watchful Waiting | -1.200% | Global, strongest in pediatric-heavy markets | Short term (≤ 2 years) |
| Treatment Failure and Recurrence | -0.900% | Global | Medium term (2-4 years) |
| Pain, Scarring, and Repeat-Visit Burden | -0.700% | North America and Europe | Short to Medium term (≤ 4 years) |
| Limited Disease-Specific Approval and Reimbursement | -0.800% | North America, with a partial overhang in Europe | Medium term (2-4 years) |
报告关注的关键问题
What is the forecast value of the Common warts market in 2031?
The Common warts market is forecast to reach USD 3.47 billion by 2031, growing at a 4.87% CAGR from 2026. The outlook reflects persistent lesions, consumer self-treatment, and specialist care pathways across the Common warts market. This pattern supports steady demand across care settings.
Which treatment type has the largest role in common wart care?
Topical medications held 43.87% of treatment-type value in 2025, supported by widely available salicylic acid products.
Which patient group is expected to grow the fastest?
Adults are forecast to grow at a 5.88% CAGR through 2031, supported by greater treatment seeking for persistent or inconvenient lesions.
Why do patients move from home treatment to dermatology clinics?
They may seek specialist care after OTC products fail, when lesions recur, or when a lesion needs cryotherapy, laser treatment, or another supervised approach
Which region is projected to grow fastest for common wart treatment?
Asia-Pacific is projected to grow at a 6.32% CAGR through 2031, supported by OTC access and clinical development activity.
Which prescription programs are advancing for common warts?
CANDIN reported positive Phase 3 results in May 2026, while YCANTH continued through Phase 3 development.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：低
查看来源：Mordor Intelligence